

Synopsis

The main focus of this survey is to study the global pharmaceutical market at three levels: global, regional and company. At the global level the pharmaceutical market grew at the lowest rate in five years in 2005, in part due to USD12 billion worth of drugs coming off patent. Europe and North America have increased their share of the market at the expense of Japan.

At the regional level, although the US remains the largest market by far and accounts for over 40% of the market, growth was significantly higher in the UK, Europe and Brazil in 2005.

Pfizer remains the number one pharmaceutical company with 2005 revenue of USD51.29 billion, but this was less than 2004 revenue. Out of the top ten companies only four registered positive revenue growth, the highest being Novartis at over 14%.

The survey updates the reportSURE 2004 survey to full year 2005 where possible.

CONTENTS

1. EXECUTIVE SUMMARY	10
2. HIGHLIGHTS	14
3. INDUSTRY OVERVIEW	18
3.1 Global pharmaceutical market	18
3.2 Segmentation of the market	19
3.2.1 Geographic segmentation	
3.2.2 Therapeutic segmentation	
3.3 Major therapeutic classes	21
3.4 Major products	22
3.5 Demand–supply	23
3.6 Trends shaping the pharmaceutical industry	24
3.6.1 Increasing consolidation	
3.6.2 Increasing outsourcing market	
3.6.3 Geographical shift	
3.6.4 Increasing R&D costs	
3.6.5 Increasing dependence on biotechnology	
3.7 Conclusion	27
3.8 Bibliography	29
4. GROWTH DRIVERS	31
4.1 Introduction	31
4.2 Major growth drivers	31
4.2.1 Increase in aging population	
4.2.2 Shifting disease patterns	
4.2.3 Increasing healthcare expenditure	
4.2.4 Increasing biotechnology based products	
4.2.5 Direct-to-consumer advertising	
4.2.6 Technological developments	
4.3 Conclusion	36
4.4 Bibliography	36
5. ISSUES AND CHALLENGES	38
5.1 Introduction	38
5.2 Major issues and challenges	38
5.2.1 Decreasing R&D productivity	
5.2.2 Tightened regulatory environment	
5.2.3 Increase in patent expiries	
5.2.4 Pricing pressure owing to intense competition	
5.2.5 Realization from partnering arrangements	

Contents table 2

5.2.6 Maximizing marketing productivity	
5.2.7 Parallel trade in the European Union	
5.3 Conclusion	42
5.4 Bibliography	42
6. TECHNOLOGY	44
6.1 Introduction	44
6.2 Technology in drug development	44
6.2.1 Combinatorial chemistry and high throughput screening	
6.2.2 Chemoinformatics	
6.2.3 Medical imaging	
6.2.4 Pharmacogenomics	
6.3 Technology in drug delivery	46
6.3.1 Nanotechnology in drug delivery	
6.3.2 Transdermal drug delivery	
6.3.3 Chronopharmaceutical delivery	
6.4 Technology in manufacturing	47
6.4.1 Process Analytical Technology	
6.5 Technology in marketing	48
6.5.1 Customer relationship management	
6.6 New technologies	48
6.6.1 Super computers in drug discovery	
6.6.2 Polymorph screening	
6.6.3 Microdosing in clinical trials	
6.7 Conclusion	50
6.8 Bibliography	50
7. MAJOR MARKETS	53
7.1 Introduction	53
7.2 US	53
7.2.1 Market size	
7.2.2 Market segmentation	
7.2.3 Major players	
7.2.4 Outlook	
7.2 Japan	56
7.2.1 Market size	
7.2.2 Market segmentation	
7.2.3 Outlook	
7.3 Europe	58
7.3.1 Market size	
7.3.2 Major markets	
7.3.3 Outlook	
7.4 UK	59
7.4.1 Market size	
7.4.2 Market segmentation	
7.4.3 Outlook	
7.5 Emerging markets	61
7.5.1 Mexico	
7.5.2 Brazil	
7.5.3 China	
7.6 Conclusion	67
7.7 Bibliography	68
8. MAJOR PLAYERS	69
8.1 Pfizer	69
8.1.1 Business profile	
8.1.2 Financial profile	

Contents table 3

8.1.3 Stock performance	
8.1.4 Key strategies	
8.1.5 Outlook	
8.1.6 Intellectual property assets	
8.2 Johnson & Johnson	73
8.2.1 Business profile	
8.2.2 Financial profile	
8.2.3 Stock performance	
8.2.4 Key strategies	
8.2.5 Outlook	
8.2.6 Intellectual property assets	
8.3 Glaxo SmithKline	77
8.3.1 Business profile	
8.3.2 Financial profile	
8.3.3 Stock performance	
8.3.4 Key strategies	
8.3.5 Outlook	
8.3.6 Intellectual property assets	
8.4 Sanofi-Aventis	82
8.4.1 Business profile	
8.4.2 Financial profile	
8.4.3 Stock performance	
8.4.4 Key strategy	
8.4.5 Outlook	
8.4.6 Intellectual property assets	
8.5. Novartis	86
8.5.1 Business profile	
8.5.2 Financial profile	
8.5.3 Stock performance	
8.5.4 Key strategies	
8.5.5 Outlook	
8.5.6 Intellectual property assets	
8.6 Roche	92
8.6.1 Business Profile	
8.6.2 Financial profile	
8.6.3 Stock performance	
8.6.4 Key strategies	
8.6.5 Outlook	
8.6.6 Intellectual property assets	
8.7 AstraZeneca	96
8.7.1 Business profile	
8.7.2 Financial profile	
8.7.3 Stock performance	
8.7.4 Key strategies	
8.7.5 Outlook	
8.7.6 Intellectual property assets	
8.8 Merck	100
8.8.1 Business profile	
8.8.2 Financial profile	
8.8.3 Stock performance	
8.8.4 Key strategies	
8.8.5 Outlook	
8.8.6 Intellectual property assets	
8.9 Bristol-Myers Squibb	104
8.9.1 Business profile	
8.9.2 Financial profile	
8.9.3 Stock performance	
8.9.4 Key strategies	

Contents table 4

8.9.5 Outlook	
8.9.6 Intellectual property assets	
8.10 Wyeth	107
8.10.1 Business profile	
8.10.2 Financial profile	
8.10.3 Stock performance	
8.10.4 Key strategies	
8.10.5 Outlook	
8.10.6 Intellectual property assets	
8.11 Conclusion	111
8.12 Bibliography	112
9. REGULATORY ASPECTS	114
9.1 Introduction	114
9.2 Regulatory bodies	114
9.2.1 US	
9.2.2 European Union	
9.2.3 Japan	
9.3 Laws governing the industry	116
9.3.1 Regulations in the US	
9.3.2 Regulations in Japan	
9.3.3 Regulations in Europe	
9.4 International agreements on intellectual property rights protection	130
9.4.1 General Agreement on Tariffs and Trade (GATT)	
9.4.2 Trade Related Aspects of Intellectual Property Rights (TRIPS)	
9.4.3 The Paris Convention (PCPIP)	
9.4.4 The Patent Co-operation Treaty (PCT)	
9.5 Prolonging Patent Protection	136
9.5.1 GATT and TRIPS	
9.5.2 The Waxman-Hatch Act	
9.6 Recent regulatory amendments	138
9.6.1 US	
9.6.2 EU	
9.6.3 Japan	
9.7 Conclusion	140
9.8 Bibliography	141
10. MERGERS & ACQUISITIONS	142
10.1 Introduction	142
10.2 M&A drivers	142
10.2.1 Need for low cost pharmaceuticals	
10.2.2 Growing generics market	
10.2.3 Replenishment of decreasing R&D pipeline and shrinking patented drug list	
10.2.4 Focus on areas of core competence	
10.3 M&A trends	144
10.3.1 Pharmaceutical M&A accounted for more than one-fourth of total healthcare M&A in deal value	
10.3.2 Pharmaceutical deals declined in terms of number and value in 2005	
10.3.3 Smaller value deals dominated the M&A scenario in 2005	
10.3.4 Top 10 M&A deals (2005, 2004 and 2003)	
10.4 Impact of Hexal and Eon Labs acquisition on Sandoz (generic subsidiary of Novartis)	147
10.4.1 Financial impact	
10.4.2 Impact on product portfolio	
10.4.3 Impact on market penetration	

Contents table 5

10.5 Conclusion	149
10.6 Bibliography	149
11. CRITICAL SUCCESS FACTORS	150
11.1 Introduction	150
11.2 Success factors	150
11.2.1 Alliances and acquisitions	
11.2.2 Outsourcing to low cost destinations	
11.2.3 Absorption of technological innovations	
11.2.4 Improving sales force effectiveness	
11.2.5 Critical mass	
11.2.6 Need for blockbuster drugs	
11.3 Conclusion	155
11.4 Bibliography	155
12. FUTURE OUTLOOK	157
12.1 Bibliography	159